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a  b  s  t  r  a  c  t
Itajaí is a port city in southern Brazil with one of the highest incidence and mortality rates
from  AIDS in the country. The prevalence and incidence of HIV infection were investigated
in  1085 of 3196 new HIV-1 infection cases evaluated in the counseling and testing center of
Itajaí from January 2002 to August 2008. Recent infections were assessed using the BEDTM,
and  pol region sequencing was performed in 76 samples. The prevalence ranged from 3.08%
to  6.17% among women and from 10.26% to 17.36% among men. A total of 17% of infections
were classiﬁed as recent, with annual incidence varying from 1.6% to 4.8 per 100 patient/year
among women and from 2.05% to 8.5 per 100 patient/year among men. Pol sequences were
obtained from 38 randomly recent infections selected individuals: 71% were infected by
subtype C, 24% B, 2% D, and 2% F1. Among 38 subjects with established infection, 76% were
subtype C, and 24% B. Transmitted drug resistance was detected in 18.4% of recent infection
subjects (7.8% to nucleoside analog reverse-transcriptase inhibitors, 5.2% to non-nucleoside
reverse-transcriptase inhibitors, and 5.2% protease inhibitors) and 5.2% of subjects with
established infection had nucleoside analog reverse-transcriptase inhibitors resistance.The high prevalence and incidence of HIV infection in this region is unprecedented in
studies involving cases evaluated in the counseling and testing centers in Brazil.
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Introduction
From 1982 to June 2012, 656,701 cases of AIDS were reported
in Brazil.1 Brazil is divided into ﬁve macroregions: north,
northeast, midwest, southeast, and south. The southeast and
south regions are the most economically developed and have
the highest number of AIDS cases in the country. In con-
trast, the mortality rate from AIDS is higher in the poorer
regions of the country.1 An interesting peculiarity has been
reported in Itajaí, a city located in the state of Santa Cata-
rina in southern Brazil. This port city, with approximately
185,000 inhabitants, often leads the ranks in the number of
AIDS cases per 100,000 inhabitants2 and of mortality rates
from AIDS.1
Several studies have been conducted in Brazil to evalu-
ate the genetic diversity of HIV-1 in the country and have
revealed the presence of subtypes B, F, C, and a signiﬁcant
number of recombinant subtypes.3,4 Subtype B virus is the
most prevalent throughout the country, whereas subtype C
virus and its recombinant forms are highly prevalent in south-
ern Brazil.3,4 The prevalence of transmitted drug resistance
(TDR) to antiretroviral agents in Brazil is considered moderate,
typically ranging from 5% to 10%.5
In this study, we  analyzed the prevalence and incidence
of HIV-1 infection in a counseling and testing center (CTC) in
Itajaí to gain further insight into the high incidence of AIDS
and high HIV-related mortality.
Materials  and  methods
This is a retrospective analysis evaluating stored sera sam-
ples and data registered in medical ﬁles. From January 2002 to
August 2008, we  evaluated 1085 patients from the CTC in Itajaí
who  were diagnosed with HIV-1. The patients had never used
antiretroviral drugs, and HIV serology was conﬁrmed with two
ELISA tests and western blotting. Serum samples were sent
to the Retrovirology Laboratory at the Federal University of
São Paulo, where further laboratory tests were performed. The
study was approved by the Institution’s Research Ethics Com-
mittee.
To determine recent infection (RI), the AWARETM BEDTM EIA
HIV-1 incidence test was used according to the manufacturer’s
instructions, and the incidence was calculated according to
previously established guidelines.6
To determine the HIV-1 subtypes and the occurrence of
TDR, 38 samples were randomly selected from subjects with
RI and 38 samples from subjects with established infection
(EI). All samples were processed as previously described.7
TDR was evaluated according to an algorithm that excludes
common polymorphisms.8 The proﬁle of HIV-1 subtypes
was determined using REGA HIV-1 Subtyping tool ver-
sion 2.0 (http://www.bioafrica.net/rega-genotype/html/index.
html).
For statistical analysis, calculations were performed to
determine the prevalence and estimated incidence rates
of infection.6 Moreover, parametric and nonparametric
distribution tests, as well as descriptive analyses, were
performed. 1 5;1  9(6):631–635
Results
Between January 2002 and August 2008, 41,115 subjects visited
the CTC in Itajaí. Among them, 3196 subjects had positive HIV
serology, and 1085 subjects were enrolled in the study. The
prevalence and incidence rates of HIV infection according to
year and gender are shown in Table 1.
New cases of HIV-1 infection during the study period were
diagnosed through serological testing of the biological mate-
rial provided by the CTC in Itajaí, state of Santa Catarina (SC).
Male/female ratios obtained were 1.4:1 in 2002, 1:1 in 2003, 1:1
in 2004, 1.3:1 in 2005, 1.2:1 in 2006, 1.2:1 in 2007, and 1.4:1 in
2008. In 2008, the ratio was estimated proportionately because
data were collected only until August.
Of the 1085 patients enrolled in the study, 519 (48%) were
women, among whom 40 (8%) were pregnant. Their age ranged
from 1.8 to 76 years, with a mean age of 34.90 ± 11.16 years and
a median age of 34 years.
Regarding sexual orientation, 834 (81%) subjects were het-
erosexuals, 35 (3%) male homosexuals, 14 (1%) bisexual, and
150 (15%) did not answer the question. Furthermore, 785 (72%)
subjects reported having acquired HIV through sexual inter-
course: 33 (3%) through blood transfusion, 63 (6%) through
injection drug use (IDU), 44 (4%) by vertical transmission, 2
(0.2%) through exposure to HIV-contaminated biological mate-
rial, and 156 (14%) did not answer the question. Regarding
the number of sexual partners per year, 10 (1%) respondents
reported having no partners in the last year; 626 (61%) had 1
partner; 21 (1%) had 2 partners; 106 (10%) had 3 partners; 36
(3%) had 4–10 partners; 30 (3%) had more  than 10 partners;
and 204 (20%) did not answer the question. Regarding use of
condoms, 488 (62%) reported not having used condoms; 148
(19%) reported sporadic use; 104 (13%) reported use of con-
doms in all sexual relations; and 45 (6%) did not answer the
question.
Concerning HIV-1 subtypes among people with RI, 9 sub-
jects (24%) were infected by subtype B, 27 (71%) by subtype C,
1 (2%) by subtype D, and 1 (2%) by subtype F1. Among the sub-
jects with EI, 9 (24%) were infected by subtype B, and 29 (76%)
by subtype C.
The prevalence of TDR was 18.4% (7 subjects, 95% CI:
8.3–34.9) among subjects with RI, of which 3 (7.8%) sub-
jects had virus resistant to nucleoside reverse transcriptase
inhibitors (NRTI; including mutations M41L, T215S, D67N,
K70R, K219Q, and L210W), 2 (5.2%) were infected by virus
resistant to non-nucleoside reverse transcriptase inhibitors
(NNRTI; mutations Y181C and G190E), and 2 (5.2%) had viral
resistant to protease inhibitors (PI; mutations V82A and I47V).
Among subjects with EI, the prevalence of TDR was 5.2% (2 sub-
jects, 95% CI: 0.9–19.1), both of which had resistance to NRTI
(mutations M41L, T215S, D67N, T69D, and K219Q).
There were no signiﬁcant gender, age, level of education,
epidemiology of HIV acquisition, HIV subtypes, and TDR dif-
ferences.Discussion
This study reports an unprecedented high prevalence and inci-
dence rates of HIV infection in Brazil (Table 2). Furthermore, it
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Table 1 – Prevalence and incidence among males and females from 2002 to 2008.
Year Female
prevalences
95%  CI Male
prevalences
95%  CI Total
prevalence
95%  CI Female
incidence
(per 100 PY)
95% CI Male
incidence
(per 100 PY)
95% CI Total
incidence
(per 100 PY)
95%  CI
2002 6.00% 5.30–6.70 17.36% 15.56–19.16 10.67% 9.83–11.51 4.08 2.38–7.78 8.50 5.50–11.50 4.34 3.18–5.50
2003 6.17% 5.47–6.87 14.34% 12.74–15.94 9.54% 8.78–10.3 2.42 1.32–3.52 3.71 1.41–6.01 2.83 1.79–3.87
2004 4.26% 3.73–4.79 10.26% 8.93–11.59 6.54% 5.95–7.13
2005 4.50% 3.93–5.07 11.75% 10.35–13.15 7.49% 6.84–8.14 1.60 0.20–3.44 2.05 0.09–4.01 1.98 0.04–3.92
2006 4.02% 3.57–4.47 10.39% 9.26–11.52 6.56% 6.04–7.08 2.66 1.42–3.90 4.96 2.26–7.66 3.44 2.21–4.67
2007 4.37% 3.86–4.88 11.05% 9.78–12.32 7.03% 6.45–7.61 3.17 1.45–4.89 7.50 4.04–10.96 4.23 2.74–5.72
2008 3.08% 2.62–3.54 10.29% 9.13–11.45 5.51% 4.92–6.10 2.79 1.65–3.93 7.80 3.98–11.62 4.33 3.64–5.02
CI, conﬁdence interval.
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Table 2 – Prevalence and incidence studies among Brazilian populations using incidence HIV-1 assays.
References Year Period
(years)
n  RI Prevalence Female
prevalence
Male
prevalence
Total
incidence
(per  100 PY)
95% CI Female
prevalence
(per 100 PY)
Male
prevalence
(per 100 PY)
Alves et al15 2003 4 350 36 (10.2%) 7.10% 5.10% 9.10% 2.00 1.1–3.5% 1.20 2.70
de Freitas Oliveira et al16 2005 11 106 18 (17%) NA NA 0.20 0.041–0.608% NA NA
Mercon et al17 2009 0.92 553 47 (8.5%) 7.50% NA NA 1.39 1.19–1.59% NA NA
Bassichetto et al18 2009 0.50 194 29 (15%) 3.20% 2.1% 4% 0.53 0.31–0.85% 0.22 0.53
de Castro et al19 2010 1 434 61 (14%) 4.80% NA NA 1.68 1.26–2.10% NA NA
Lima et al20 2011 3 375 105 (28%) 1310.00% 0.87% 2.80% 1.31 0.61–0.86% 0.55 1.34
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orroborates important ﬁndings regarding the feminization of
he HIV epidemic in the country. It has been reported that,
n general, the ratio of infected men/infected women has
ecreased from 26.3/1 in the mid-1980s to approximately 1.5/1
n more  recent years.1
Overall, the demographic proﬁle of the subjects being eval-
ated in the CTC of Itajaí is similar to that found in other
xisting CTCs in Brazil (data not shown). The subtype proﬁle of
he study group revealed a high prevalence of subtype C virus,
hich is in agreement with previous studies, demonstrating
he high prevalence of this subtype in southern Brazil.3 Sim-
larly, the prevalence of TDR and the mutation proﬁle in this
mall sample are in line with previous studies conducted in
ther regions of Brazil.5
We  acknowledge that tests for detecting recent infections,
uch as the BED assay, may eventually present ﬂaws6,9–11
nd validation studies using subtype C virus are scarce.12–14
oreover, we recognize that the number of subjects tested to
etermine viral subtypes and TDR was limited in this study.
owever, it is of note that the high prevalence and incidence
ates of HIV-1 infection in Itajaí, a city with a known high
revalence of AIDS and HIV-related mortality, is unprece-
ented in Brazil. Therefore, efforts should be made to identify
he causes of the problem, decrease the mortality rate from
IDS, and interrupt the transmission cycle. Furthermore, the
roﬁle of subjects with recent HIV-1 infection should be better
haracterized.
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